RxDoctor Payments Data

Douglas Pinto, MD

Internal Medicine · Catonsville, MDNPI 1790745750

Payments from drug & device makers

$1,140in general payments, 2019–2025

Across 64 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$150
  • Amgen$121
  • Astellas Pharma US Inc$103
  • AstraZeneca$97
  • Kowa Pharmaceuticals America, Inc.$71
  • Boehringer Ingelheim$71
  • plus $527 from 15 others

What the payments were for

  • Food & beverage$1,01989%
  • Education$12111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,140 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$89,888
Medicare patients
221
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$46,886
EliquisApixaban38$40,628
XareltoRivaroxaban27$33,400
JanuviaSitagliptin Phosphate19$28,194
OzempicSemaglutide19$23,996
MounjaroTirzepatide20$20,474
MyrbetriqMirabegron17$14,428
Tresiba Flextouch U-200Insulin Degludec15$12,211
Ezetimibe212$12,189
Rosuvastatin Calcium383$10,256
NexletolBempedoic Acid23$9,814
Colchicine81$8,356
Repatha SureclickEvolocumab14$7,719
PaxlovidNirmatrelvir/Ritonavir22$5,718
Breo ElliptaFluticasone/Vilanterol14$5,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$71$46,88627 claims
PfizerEliquis, Paxlovid$52$46,34660 claims
Johnson & JohnsonXarelto$62$33,40027 claims
MerckJanuvia$13$28,19419 claims
Novo NordiskOzempic$150$23,99619 claims
Lilly USA, LLCMounjaro$61$20,47420 claims
Astellas Pharma US IncMyrbetriq$103$14,42817 claims
GSKBreo Ellipta$34$5,47214 claims
Kowa Pharmaceuticals America, Inc.Livalo$71$3,69212 claims
AbbVieSynthroid$14$1,71533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Catonsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →